Drug Information

Drug General Information
Drug ID
D03PGF
Former ID
DNC012702
Drug Name
RPR-118723
Drug Type
Small molecular drug
Indication Discovery agent Investigative [525816]
Structure
Download
2D MOL

3D MOL
Formula
C14H11ClN2O4
Canonical SMILES
CC1(C2=C(C=C(C=C2)Cl)C3=C1NC(=O)C(=O)N3)CC(=O)O
InChI
1S/C14H11ClN2O4/c1-14(5-9(18)19)8-3-2-6(15)4-7(8)10-11(14)17-13(21)12(20)16-10/h2-4H,5H2,1H3,(H,16,20)(H,17,21)(H,18,19)
InChIKey
XNLOOYJBLRHTMX-UHFFFAOYSA-N
PubChem Compound ID
9796571
Target and Pathway
Target(s) Glutamate receptor 1 Target Info Inhibitor [525816]
NMDA receptor subunit NR1 Target Info Inhibitor [525816]
Glutamate [NMDA] receptor subunit epsilon 2 Target Info Inhibitor [525816]
Glutamate [NMDA] receptor subunit epsilon 1 Target Info Inhibitor [525816]
Glutamate receptor AMPA subtype Target Info Inhibitor [525816]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Circadian entrainment
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Dopaminergic synapse
Long-term depression
Amyotrophic lateral sclerosis (ALS)
Amphetamine addiction
Nicotine addictionhsa04014:Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Alzheimer's disease
Huntington's disease
Cocaine addiction
Nicotine addiction
Alcoholismhsa04014:Ras signaling pathway
Alcoholism
Systemic lupus erythematosushsa04014:Ras signaling pathway
Systemic lupus erythematosus
PANTHER Pathway Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathwayP00029:Huntington disease
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Pathway Interaction Database EPHB forward signalingerbb4_pathway:ErbB4 signaling events
Reelin signaling pathwayreelinpathway:Reelin signaling pathway
Reactome COPII (Coat Protein 2) Mediated Vesicle Transport
Trafficking of AMPA receptors
Trafficking of GluR2-containing AMPA receptors
Unblocking of NMDA receptor, glutamate binding and activation
Cargo concentration in the ERR-HSA-3928662:EPHB-mediated forward signaling
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
RAF/MAP kinase cascade
WikiPathways Hypothetical Network for Drug Addiction
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Amyotrophic lateral sclerosis (ALS)
BDNF signaling pathwayWP706:SIDS Susceptibility Pathways
Spinal Cord Injury
BDNF signaling pathway
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
Alzheimers Disease
References
Ref 525816J Med Chem. 2000 Jun 15;43(12):2371-81.Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.
Ref 525816J Med Chem. 2000 Jun 15;43(12):2371-81.Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.